Please Wait
Applying Filters...
menu
    • menu
    Gangwal Healthcare is powered by innovation, driving health, wellness & healing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Synnat Pharma is one of the leading active pharmaceutical ingredients and intermediates manufacturers.

    Virtual Booth

    Contact Supplier

    Rusan Pharma: Over 30 years of specializing in the treatment of Addiction and Pain Management.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Milademetan

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Rain Therapeutics Provides Interim Analysis of Ph2 Basket Trial of Milademetan
    Rain Therapeutics Provides Interim Analysis of Ph2 Basket Trial of Milademetan

    04 Nov 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/11/04/2548698/0/en/Rain-Therapeutics-Provides-Interim-Analysis-of-Phase-2-Basket-Trial-of-Milademetan-for-MDM2-Amplified-Advanced-Solid-Tumors-MANTRA-2.html

    GLOBENEWSWIRE
    04 Nov 2022
    Share Share
    Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
    Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference

    31 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/31/2507565/0/en/Rain-Therapeutics-to-Participate-in-Citi-s-17th-Annual-BioPharma-Conference.html

    GLOBENEWSWIRE
    31 Aug 2022
    Share Share
    Rain Tx Completes Enrollment in PIII MANTRA Trial for Milademetan in Liposarcoma
    Rain Tx Completes Enrollment in PIII MANTRA Trial for Milademetan in Liposarcoma

    04 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/04/2492298/0/en/Rain-Therapeutics-Announces-Completion-of-Enrollment-in-Phase-3-MANTRA-Trial-for-Milademetan-in-Liposarcoma.html

    GLOBENEWSWIRE
    04 Aug 2022
    Share Share
    Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
    Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

    18 May 2022

    // PRESS RELEASE

    https://www.rainthera.com/news-press-releases/rain-therapeutics-to-present-on-milademetan-at-the-2022-american-society-of-clinical-oncology-asco-annual-meeting

    PRESS RELEASE
    18 May 2022
    Share Share
    Rain Therapeutics Presents Non-Clinical Data on Milademetan in MPM
    Rain Therapeutics Presents Non-Clinical Data on Milademetan in MPM

    08 Sep 2021

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2021/09/08/2293342/0/en/Rain-Therapeutics-Presents-Non-Clinical-Data-on-Milademetan-RAIN-32-in-Malignant-Pleural-Mesothelioma-at-the-IASLC-2021-World-Conference-on-Lung-Cancer.html

    GLOBENEWSWIRE
    08 Sep 2021
    Share Share
    Daiichi Sankyo Initiates Combination Study of 2 Investgl Agents AML
    Daiichi Sankyo Initiates Combination Study of 2 Investgl Agents AML

    20 Dec 2018

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/daiichi-sankyo-initiates-first-novel-novel-combination-study-of-two-investigational-agents-within-its-aml-franchise-in-patients-with-aml-300768455.html

    PR NEWSWIRE
    20 Dec 2018
    Share Share